The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-12

AUTHORS

Isabelle Durand-Zaleski, Michel Bertrand

ABSTRACT

Atherothrombotic disease is a growing health problem, and is increasingly more costly to manage. Clopidogrel is an advanced, specific adenosine diphosphate receptor antagonist, which has been shown to be a highly potent antiplatelet agent. Data from the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study have demonstrated the significantly superior clinical benefit of clopidogrel over aspirin for secondary prevention of atherothrombotic disease, with a relative risk reduction in myocardial infarction, stroke or vascular death of 8.7% (95% confidence interval 0.3, 16.5; P = 0.043). Moreover, clopidogrel demonstrated an amplified clinical benefit versus aspirin in patients at high risk of atherothrombotic events, such as those with a previous history of symptomatic atherothrombotic disease or with major risk factors such as diabetes mellitus or hypercholesterolaemia. On the basis of commonly accepted threshold criteria (€20 000 per life-year gained; LYG), clopidogrel in comparison with aspirin is cost-effective for the secondary prevention of atherothrombotic disease (cost per LYG ranging from €19 462 to €3256). Economic analyses have demonstrated consistent cost-effectiveness results with clopidogrel in different countries. Moreover, in high-risk patient subgroups the cost-effectiveness of clopidogrel in comparison with aspirin was even better (cost per LYG ranging from €5900 to €6310). Compared with other treatment strategies used for the prevention of ischaemic or atherothrombotic events, the cost-effectiveness of clopidogrel in comparison with aspirin based on CAPRIE is favourable, with most analyses in the intermediate range of cost-effectiveness. The available data thus support the use of clopidogrel as a clinically efficient and cost-effective option for secondary prevention of atherothrombotic disease, particularly in high-risk patients. More... »

PAGES

19-27

References to SciGraph publications

  • 2002-06. Macroeconomics and Health: Investing in Health for Economic Development in NATURE MEDICINE
  • 2001-12. Paclitaxel in PHARMACOECONOMICS
  • 2000-08. Clopidogrel in DRUGS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00019053-200422004-00005

    DOI

    http://dx.doi.org/10.2165/00019053-200422004-00005

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1047977620

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15876009


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Arterial Occlusive Diseases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aspirin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clopidogrel", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cost-Benefit Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Multicenter Studies as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Randomized Controlled Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ticlopidine", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Public Health Service, Henri Mondor Hospital, Assistance Publique-H\u00f4pitaux de Paris, 51 avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Creteil, France", 
              "id": "http://www.grid.ac/institutes/grid.412116.1", 
              "name": [
                "Public Health Service, Henri Mondor Hospital, Assistance Publique-H\u00f4pitaux de Paris, 51 avenue du Mar\u00e9chal de Lattre de Tassigny, 94010, Creteil, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Durand-Zaleski", 
            "givenName": "Isabelle", 
            "id": "sg:person.01327533357.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cardiology, Ho\u00f4pital Cardiologique, Lille, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Cardiology, Ho\u00f4pital Cardiologique, Lille, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bertrand", 
            "givenName": "Michel", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nm0602-551b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009367418", 
              "https://doi.org/10.1038/nm0602-551b"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00019053-200119120-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027263347", 
              "https://doi.org/10.2165/00019053-200119120-00005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-200060020-00012", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022414924", 
              "https://doi.org/10.2165/00003495-200060020-00012"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-12", 
        "datePublishedReg": "2004-12-01", 
        "description": "Atherothrombotic disease is a growing health problem, and is increasingly more costly to manage. Clopidogrel is an advanced, specific adenosine diphosphate receptor antagonist, which has been shown to be a highly potent antiplatelet agent. Data from the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study have demonstrated the significantly superior clinical benefit of clopidogrel over aspirin for secondary prevention of atherothrombotic disease, with a relative risk reduction in myocardial infarction, stroke or vascular death of 8.7% (95% confidence interval 0.3, 16.5; P = 0.043). Moreover, clopidogrel demonstrated an amplified clinical benefit versus aspirin in patients at high risk of atherothrombotic events, such as those with a previous history of symptomatic atherothrombotic disease or with major risk factors such as diabetes mellitus or hypercholesterolaemia. On the basis of commonly accepted threshold criteria (\u20ac20 000 per life-year gained; LYG), clopidogrel in comparison with aspirin is cost-effective for the secondary prevention of atherothrombotic disease (cost per LYG ranging from \u20ac19 462 to \u20ac3256). Economic analyses have demonstrated consistent cost-effectiveness results with clopidogrel in different countries. Moreover, in high-risk patient subgroups the cost-effectiveness of clopidogrel in comparison with aspirin was even better (cost per LYG ranging from \u20ac5900 to \u20ac6310). Compared with other treatment strategies used for the prevention of ischaemic or atherothrombotic events, the cost-effectiveness of clopidogrel in comparison with aspirin based on CAPRIE is favourable, with most analyses in the intermediate range of cost-effectiveness. The available data thus support the use of clopidogrel as a clinically efficient and cost-effective option for secondary prevention of atherothrombotic disease, particularly in high-risk patients.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00019053-200422004-00005", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1102812", 
            "issn": [
              "1170-7690", 
              "1179-2027"
            ], 
            "name": "PharmacoEconomics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "Suppl 4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "22"
          }
        ], 
        "keywords": [
          "atherothrombotic disease", 
          "secondary prevention", 
          "atherothrombotic events", 
          "clinical benefit", 
          "adenosine diphosphate receptor antagonists", 
          "high-risk patient subgroups", 
          "diphosphate receptor antagonists", 
          "symptomatic atherothrombotic disease", 
          "use of clopidogrel", 
          "superior clinical benefit", 
          "high-risk patients", 
          "relative risk reduction", 
          "major risk factor", 
          "potent antiplatelet agents", 
          "Ischemic Events (CAPRIE) study", 
          "cost-effectiveness results", 
          "vascular death", 
          "CAPRIE study", 
          "antiplatelet agents", 
          "diabetes mellitus", 
          "patient subgroups", 
          "receptor antagonist", 
          "myocardial infarction", 
          "risk factors", 
          "treatment strategies", 
          "clopidogrel", 
          "high risk", 
          "previous history", 
          "aspirin", 
          "health problems", 
          "patients", 
          "disease", 
          "prevention", 
          "cost-effective option", 
          "risk reduction", 
          "risk", 
          "CAPRIE", 
          "mellitus", 
          "hypercholesterolaemia", 
          "infarction", 
          "antagonist", 
          "stroke", 
          "available data", 
          "death", 
          "subgroups", 
          "events", 
          "study", 
          "benefits", 
          "threshold criteria", 
          "options", 
          "agents", 
          "different countries", 
          "factors", 
          "data", 
          "history", 
          "criteria", 
          "comparison", 
          "reduction", 
          "analysis", 
          "use", 
          "most analyses", 
          "strategies", 
          "countries", 
          "results", 
          "economic analysis", 
          "values", 
          "intermediate range", 
          "basis", 
          "range", 
          "problem", 
          "event study"
        ], 
        "name": "The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study", 
        "pagination": "19-27", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1047977620"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00019053-200422004-00005"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15876009"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00019053-200422004-00005", 
          "https://app.dimensions.ai/details/publication/pub.1047977620"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:32", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_379.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00019053-200422004-00005"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200422004-00005'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200422004-00005'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200422004-00005'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200422004-00005'


     

    This table displays all metadata directly associated to this object as RDF triples.

    189 TRIPLES      21 PREDICATES      109 URIs      97 LITERALS      15 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00019053-200422004-00005 schema:about N40146ed3501d45499e6bc4fe31990673
    2 N4ddb2ee2b5b543389ef5d7bad44095a8
    3 N7fc9d3888bb448f38c8ead3b830cbb5b
    4 N835eb8be12f84a64830ba65b56d935e2
    5 Na6a077c3d26940fe88cbd6522c49690d
    6 Nbc760e0a273c45f6a20853946c7e2f88
    7 Nc587ae3e51124a08b8b796a4e49b808d
    8 Nf865fa09cf8c461e902e68da95d603c2
    9 anzsrc-for:11
    10 anzsrc-for:1103
    11 anzsrc-for:1117
    12 schema:author N0b87c7571cf043e2b50d9d3825bed060
    13 schema:citation sg:pub.10.1038/nm0602-551b
    14 sg:pub.10.2165/00003495-200060020-00012
    15 sg:pub.10.2165/00019053-200119120-00005
    16 schema:datePublished 2004-12
    17 schema:datePublishedReg 2004-12-01
    18 schema:description Atherothrombotic disease is a growing health problem, and is increasingly more costly to manage. Clopidogrel is an advanced, specific adenosine diphosphate receptor antagonist, which has been shown to be a highly potent antiplatelet agent. Data from the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study have demonstrated the significantly superior clinical benefit of clopidogrel over aspirin for secondary prevention of atherothrombotic disease, with a relative risk reduction in myocardial infarction, stroke or vascular death of 8.7% (95% confidence interval 0.3, 16.5; P = 0.043). Moreover, clopidogrel demonstrated an amplified clinical benefit versus aspirin in patients at high risk of atherothrombotic events, such as those with a previous history of symptomatic atherothrombotic disease or with major risk factors such as diabetes mellitus or hypercholesterolaemia. On the basis of commonly accepted threshold criteria (€20 000 per life-year gained; LYG), clopidogrel in comparison with aspirin is cost-effective for the secondary prevention of atherothrombotic disease (cost per LYG ranging from €19 462 to €3256). Economic analyses have demonstrated consistent cost-effectiveness results with clopidogrel in different countries. Moreover, in high-risk patient subgroups the cost-effectiveness of clopidogrel in comparison with aspirin was even better (cost per LYG ranging from €5900 to €6310). Compared with other treatment strategies used for the prevention of ischaemic or atherothrombotic events, the cost-effectiveness of clopidogrel in comparison with aspirin based on CAPRIE is favourable, with most analyses in the intermediate range of cost-effectiveness. The available data thus support the use of clopidogrel as a clinically efficient and cost-effective option for secondary prevention of atherothrombotic disease, particularly in high-risk patients.
    19 schema:genre article
    20 schema:isAccessibleForFree false
    21 schema:isPartOf N1500c72c5d4c4647bd241d72c7831b0d
    22 N69fd59f63bf344ad8ce9bbdf8e2a5a21
    23 sg:journal.1102812
    24 schema:keywords CAPRIE
    25 CAPRIE study
    26 Ischemic Events (CAPRIE) study
    27 adenosine diphosphate receptor antagonists
    28 agents
    29 analysis
    30 antagonist
    31 antiplatelet agents
    32 aspirin
    33 atherothrombotic disease
    34 atherothrombotic events
    35 available data
    36 basis
    37 benefits
    38 clinical benefit
    39 clopidogrel
    40 comparison
    41 cost-effective option
    42 cost-effectiveness results
    43 countries
    44 criteria
    45 data
    46 death
    47 diabetes mellitus
    48 different countries
    49 diphosphate receptor antagonists
    50 disease
    51 economic analysis
    52 event study
    53 events
    54 factors
    55 health problems
    56 high risk
    57 high-risk patient subgroups
    58 high-risk patients
    59 history
    60 hypercholesterolaemia
    61 infarction
    62 intermediate range
    63 major risk factor
    64 mellitus
    65 most analyses
    66 myocardial infarction
    67 options
    68 patient subgroups
    69 patients
    70 potent antiplatelet agents
    71 prevention
    72 previous history
    73 problem
    74 range
    75 receptor antagonist
    76 reduction
    77 relative risk reduction
    78 results
    79 risk
    80 risk factors
    81 risk reduction
    82 secondary prevention
    83 strategies
    84 stroke
    85 study
    86 subgroups
    87 superior clinical benefit
    88 symptomatic atherothrombotic disease
    89 threshold criteria
    90 treatment strategies
    91 use
    92 use of clopidogrel
    93 values
    94 vascular death
    95 schema:name The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study
    96 schema:pagination 19-27
    97 schema:productId N7634efe2ab594a64aea30bd0a5097fa0
    98 N7dbcd2057e594ba3b8879b207446fc35
    99 Nee430ea33a0843d0bd7e7af7c1055c32
    100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047977620
    101 https://doi.org/10.2165/00019053-200422004-00005
    102 schema:sdDatePublished 2022-10-01T06:32
    103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    104 schema:sdPublisher N6da41266ae9e42c18c400d4b3262557d
    105 schema:url https://doi.org/10.2165/00019053-200422004-00005
    106 sgo:license sg:explorer/license/
    107 sgo:sdDataset articles
    108 rdf:type schema:ScholarlyArticle
    109 N0b87c7571cf043e2b50d9d3825bed060 rdf:first sg:person.01327533357.46
    110 rdf:rest N0e35690dec3b436495621581490671ac
    111 N0e35690dec3b436495621581490671ac rdf:first N3f4aa18fba704e76b7dc325cec0d74b8
    112 rdf:rest rdf:nil
    113 N1500c72c5d4c4647bd241d72c7831b0d schema:issueNumber Suppl 4
    114 rdf:type schema:PublicationIssue
    115 N3f4aa18fba704e76b7dc325cec0d74b8 schema:affiliation grid-institutes:None
    116 schema:familyName Bertrand
    117 schema:givenName Michel
    118 rdf:type schema:Person
    119 N40146ed3501d45499e6bc4fe31990673 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Cost-Benefit Analysis
    121 rdf:type schema:DefinedTerm
    122 N4ddb2ee2b5b543389ef5d7bad44095a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Arterial Occlusive Diseases
    124 rdf:type schema:DefinedTerm
    125 N69fd59f63bf344ad8ce9bbdf8e2a5a21 schema:volumeNumber 22
    126 rdf:type schema:PublicationVolume
    127 N6da41266ae9e42c18c400d4b3262557d schema:name Springer Nature - SN SciGraph project
    128 rdf:type schema:Organization
    129 N7634efe2ab594a64aea30bd0a5097fa0 schema:name doi
    130 schema:value 10.2165/00019053-200422004-00005
    131 rdf:type schema:PropertyValue
    132 N7dbcd2057e594ba3b8879b207446fc35 schema:name dimensions_id
    133 schema:value pub.1047977620
    134 rdf:type schema:PropertyValue
    135 N7fc9d3888bb448f38c8ead3b830cbb5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Multicenter Studies as Topic
    137 rdf:type schema:DefinedTerm
    138 N835eb8be12f84a64830ba65b56d935e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Humans
    140 rdf:type schema:DefinedTerm
    141 Na6a077c3d26940fe88cbd6522c49690d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Clopidogrel
    143 rdf:type schema:DefinedTerm
    144 Nbc760e0a273c45f6a20853946c7e2f88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Randomized Controlled Trials as Topic
    146 rdf:type schema:DefinedTerm
    147 Nc587ae3e51124a08b8b796a4e49b808d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Aspirin
    149 rdf:type schema:DefinedTerm
    150 Nee430ea33a0843d0bd7e7af7c1055c32 schema:name pubmed_id
    151 schema:value 15876009
    152 rdf:type schema:PropertyValue
    153 Nf865fa09cf8c461e902e68da95d603c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Ticlopidine
    155 rdf:type schema:DefinedTerm
    156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    157 schema:name Medical and Health Sciences
    158 rdf:type schema:DefinedTerm
    159 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    160 schema:name Clinical Sciences
    161 rdf:type schema:DefinedTerm
    162 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    163 schema:name Public Health and Health Services
    164 rdf:type schema:DefinedTerm
    165 sg:journal.1102812 schema:issn 1170-7690
    166 1179-2027
    167 schema:name PharmacoEconomics
    168 schema:publisher Springer Nature
    169 rdf:type schema:Periodical
    170 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.412116.1
    171 schema:familyName Durand-Zaleski
    172 schema:givenName Isabelle
    173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
    174 rdf:type schema:Person
    175 sg:pub.10.1038/nm0602-551b schema:sameAs https://app.dimensions.ai/details/publication/pub.1009367418
    176 https://doi.org/10.1038/nm0602-551b
    177 rdf:type schema:CreativeWork
    178 sg:pub.10.2165/00003495-200060020-00012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022414924
    179 https://doi.org/10.2165/00003495-200060020-00012
    180 rdf:type schema:CreativeWork
    181 sg:pub.10.2165/00019053-200119120-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027263347
    182 https://doi.org/10.2165/00019053-200119120-00005
    183 rdf:type schema:CreativeWork
    184 grid-institutes:None schema:alternateName Department of Cardiology, Hoôpital Cardiologique, Lille, France
    185 schema:name Department of Cardiology, Hoôpital Cardiologique, Lille, France
    186 rdf:type schema:Organization
    187 grid-institutes:grid.412116.1 schema:alternateName Public Health Service, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, 51 avenue du Maréchal de Lattre de Tassigny, 94010, Creteil, France
    188 schema:name Public Health Service, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, 51 avenue du Maréchal de Lattre de Tassigny, 94010, Creteil, France
    189 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...